Before and after cell therapy cytokines dynamics balance in multiple sclerosis patients

Zafranskaya М.М., Nizheharodava D.B., Ivanchyk H.I., Borisov A.V., Kozhuch G.V., Nazarova E.A., Fedulau А.S.

1Belarusian medical academy of post-graduate education, Minsk, Belarus;
2Belarusian state medical university, Minsk, Belarus;
3Rеpublic research and production center for transfusiology and medical biotechnologies, Minsk, Belarus;
4Minsk City Hospital N9, Minsk, Belarus

Broad-spectrum of publications has demonstrated mesenchymal stem cells (MSC) role as the important modulator of the both innate and adaptive immune responses under inflammation and damage conditions. Thereby up-to-day method of MSC therapy corresponds the promising complex approach to the multiple sclerosis (MS) combined treatment. This article examines in vitro cell therapy effect on pro-inflammatory (γIFN, TNFα) and anti-inflammatory (IL-10, TGFβ) cytokines synthesis, the balance of which determines the neuroimmune inflammation development. It was established in MS patients that MSC are capable to switch the profile of in vitro cytokines’ synthesis from pro-inflammatory to regulatory in myelin-stimulated peripheral blood mononuclear cells. The immunomodulatory effect of MSC in MS patients was expressed as the decrease of pathogenically important γIFN and TNFα production to 3d-6th months after treatment up to levels comparable with that under in vitro antigen-specific stimulation of lymphocytes and MSC co-cultures.